2017-03-004 - CARDIOCALP - CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING
Acronim & Gínjol codes
CARDIOCALP
2017-03-004
Main technology offer
Pharmacological inhibition of calpain could be a useful strategy in the treatment of adverse remodeling and pos myocardial infarction heart failure. Some companies have already shown interest in the treatment.
Ownership
Barcelona, Spain
2002
Vall d’Hebron Institut de Recerca (VHIR)
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
Market Data
Cardiovascular diseases (CVD) rank as the top world’s top cause of death, and dramatically reduce expectancy and quality of life. Many different CVD develop myocardial remodeling, characterized by an inflammatory pattern, development of hypertrophy and excessive myocardial fibrosis, leading to acute heart failure. At present there are no effective pharmacological treatments specifically addressed to prevent myocardial remodeling and its progression to heart failure. The Ca2+-dependent proteases calpains are over-expressed and over-activated during ventricular remodeling. Its specific inhibition has been shown to attenuate development of myocardial remodeling.
0
0
0
License
Overall Cardiovascular Diseases accounts for 37% of all deaths in the EU and it is estimated to cost the EU economy €210 billion a year. Heart Failure remains one of the most common reasons for hospitalization in the 7MM, accounting for almost 5% of all medical admissions in most countries. Heart Failure incidence and prevalence are on the rise, which leads to a high burden of morbidity and mortality, reduced quality of life, and increasing healthcare costs worldwide.
Patients suffering cardiovascular diseases that develop myocardial remodeling and heart failure.
Funding
Finding partnership
Partners to establish licensing agreements
Stablish a collaboration for closing preclinic studies and start clinical studies.
Technology Status
Specific calpain inhibitor with water solubility and high bioavailability. Chronic oral administration of the calpain inhibitor attenuates myocardial hypertrophy and fibrosis associated to adverse left ventricular remodeling related to both ischemic and non-ischemic cardiovascular diseases.
Finding a partner to license, finish preclinical studies and start clinical.
PCT application in 2017. Patent rights up to 2036.
Senju is not interested in developing this use for calpains.
Additional information
Patents: WO2017190894A1; PCT/EP2017/057501 - Date: Nov 9th, 2017 Status: Granted URL: https://patents.google.com/patent/WO2017190894A1/en
Patients develop myocardial remodeling and heart failure after myocardial infarction (MI) and overall CVD accounts for 37% of all deaths in the EU and it is estimated to cost the EU economy €210 billion a year. Heart Failure remains one of the most common reasons for hospitalization in the 7MM, accounting for almost 5% of all medical admissions in most countries.